Ranbaxy loses bid to block rivals in generic drugs fight
Ranbaxy loses bid for a temporary court order to block rivals' generic versions of heartburn pill Nexium and antiviral drug Valcyte
Washington: Ranbaxy Laboratories Ltd lost a bid for a temporary court order to block rivals’ generic versions of the heartburn pill Nexium and the antiviral drug Valcyte.
Ranbaxy sought the order in a lawsuit against the US Food and Drug Administration (FDA) over the agency’s revocation of tentative approval for the company to make its own generic versions of the drugs.
The FDA revocation wrongfully punishes Ranbaxy for manufacturing deficiencies found at two Indian facilities in 2006 and 2008, blocking “hundreds of millions of dollars in anticipated revenue," the company said in a complaint filed on 14 November in federal court in Washington.
Ranbaxy, based in Gurgaon, wanted the order to prevent competitors Dr. Reddy’s Laboratories Ltd and the US unit of Dublin-based Endo International Plc from moving ahead with marketing their generic versions of the compounds while its complaint was heard.
US district judge Beryl Howell on Thursday declined to restrain Endo and Dr. Reddy’s and gave Ranbaxy and the FDA until 21 November to propose a schedule for further proceedings.
A Ranbaxy representative in Gurgaon didn’t immediately respond to an email before regular business hours seeking comment on the ruling. Bloomberg
Unlock a world of Benefits! From insightful newsletters to real-time stock tracking, breaking news and a personalized newsfeed – it's all here, just a click away! Login Now!